Zoe

Where to start with an Australian legal problem: plain-English guides, with the legislation and case law behind them.

Platform

Legislation
Cases
Guides
Find a lawyer
Absurdities
Ask Zoe
Graph
Recently analysed

Free tools

Bond claim checker
Barking dog and noise diary
Support at Home statement check
All tools

Lawyers: our picks

Zoe

Where to start with an Australian legal problem: plain-English guides, with the legislation and case law behind them.

Platform

Legislation
Cases
Guides
Find a lawyer
Absurdities
Ask Zoe
Graph
Recently analysed

Free tools

Bond claim checker
Barking dog and noise diary
Support at Home statement check
All tools

Lawyers: our picks

Lawyers in Sydney
Lawyers in Melbourne
Lawyers in Brisbane
Lawyers in Perth
Family lawyers
Employment lawyers
Criminal lawyers
Wills and estates lawyers
Find a lawyer

Company

Pricing
API
Privacy
Terms
Support
X
LinkedIn
Instagram

Jurisdictions

Commonwealth
New South Wales
Queensland
Victoria
Western Australia
South Australia
Tasmania
Australian Capital Territory
Northern Territory

Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.

Part Part 3 - National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016) - General statement for drugs for the treatment of hepatitis C | Zoe

Zoe

Legislation Cases Guides Find a lawyer Absurdities Ask Zoe Graph Pricing

Ask Zoe →

Home/Legislation/National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016)/Part 3

CTHRepealedLegislation

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016)

Part 3General statement for drugs for the treatment of hepatitis C

Start here

Get a plain-English read of Part 3

Turn the raw legal text into a practical explanation grounded in National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016).

Ask Zoe about this section View in full context

Part 3—General statement for drugs for the treatment of hepatitis C

Previous sectionSch 1Amendments

Next section1Criteria for eligibility for drugs for the treatment of chronic hepatitis C